In this study, we showed the expression of both targets to be high but heterogenous among NB tumors, predicting that some of the patients with low expression of GPC2 or CD276 would not benefit from CAR T cell therapies targeting either single antigen. The gene discussed is CD276; the disease is neuroblastoma.